PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of thijTexas Heart Institute JournalSee also Cardiovascular Diseases Journal in PMCSubscribeSubmissionsTHI Journal Website
 
Tex Heart Inst J. 1995; 22(3): 216–230.
PMCID: PMC325257

Limiting excessive postoperative blood transfusion after cardiac procedures. A review.

Abstract

Analysis of blood product use after cardiac operations reveals that a few patients (< or = 20%) consume the majority of blood products (> 80%). The risk factors that predispose a minority of patients to excessive blood use include patient-related factors, transfusion practices, drug-related causes, and procedure-related factors. Multivariate studies suggest that patient age and red blood cell volume are independent patient-related variables that predict excessive blood product transfusion after cardiac procedures. Other factors include preoperative aspirin ingestion, type of operation, over- or underutilization of heparin during cardiopulmonary bypass, failure to correct hypothermia after cardiopulmonary bypass, and physician overtransfusion. A survey of the currently available blood conservation techniques reveals 5 that stand out as reliable methods: 1) high-dose aprotinin therapy, 2) preoperative erythropoietin therapy when time permits adequate dosage before operation, 3) hemodilution by harvest of whole blood immediately before cardiopulmonary bypass, 4) autologous predonation of blood, and 5) salvage of oxygenator blood after cardiopulmonary bypass. Other methods, such as the use of epsilon-aminocaproic acid or desmopressin, cell saving devices, reinfusion of shed mediastinal blood, and hemofiltration have been reported to be less reliable and may even be harmful in some high-risk patients. Consideration of the available data allows formulation of a 4-pronged plan for limiting excessive blood transfusion after surgery: 1) recognize the causes of excessive transfusion, including the importance of red blood cell volume, type of procedure being performed, preoperative aspirin ingestion, etc.; 2) establish a quality management program, including a survey of transfusion practices that emphasizes physician education and availability of real-time laboratory testing to guide transfusion therapy; 3) adopt a multimodal approach using institution-proven techniques; and 4) continually reassess blood product use and analyze the cost-benefits of blood conservation interventions.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ward JW, Holmberg SD, Allen JR, Cohn DL, Critchley SE, Kleinman SH, Lenes BA, Ravenholt O, Davis JR, Quinn MG, et al. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med. 1988 Feb 25;318(8):473–478. [PubMed]
  • Collins JD, Bassendine MF, Codd AA, Collins A, Ferner RE, James OF. Prospective study of post-transfusion hepatitis after cardiac surgery in a British centre. Br Med J (Clin Res Ed) 1983 Nov 12;287(6403):1422–1424. [PMC free article] [PubMed]
  • Murphy PJ, Connery C, Hicks GL, Jr, Blumberg N. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. J Thorac Cardiovasc Surg. 1992 Oct;104(4):1092–1099. [PubMed]
  • Breyer RH, Engelman RM, Rousou JA, Lemeshow S. Blood conservation for myocardial revascularization. Is it cost effective? J Thorac Cardiovasc Surg. 1987 Apr;93(4):512–522. [PubMed]
  • Goodnough LT, Soegiarso RW, Birkmeyer JD, Welch HG. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med. 1993 May;94(5):509–514. [PubMed]
  • Graves EJ. National hospital discharge survey: annual summary, 1991. Vital Health Stat 13. 1993 Jul;(114):1–62. [PubMed]
  • LoCicero J, 3rd, Massad M, Gandy K, Sanders JH, Jr, Hartz RS, Frederiksen JW, Michaelis LL. Aggressive blood conservation in coronary artery surgery: impact on patient care. J Cardiovasc Surg (Torino) 1990 Sep-Oct;31(5):559–563. [PubMed]
  • Jones JW, Rawitscher RE, McLean TR, Beall AC, Jr, Thornby JI. Benefit from combining blood conservation measures in cardiac operations. Ann Thorac Surg. 1991 Apr;51(4):541–546. [PubMed]
  • Scott WJ, Rode R, Castlemain B, Kessler R, Follis F, Pett SB, Wernly JA. Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg. 1992 May;103(5):1001–1007. [PubMed]
  • Ferraris VA, Gildengorin V. Predictors of excessive blood use after coronary artery bypass grafting. A multivariate analysis. J Thorac Cardiovasc Surg. 1989 Oct;98(4):492–497. [PubMed]
  • Scott WJ, Kessler R, Wernly JA. Blood conservation in cardiac surgery. Ann Thorac Surg. 1990 Nov;50(5):843–851. [PubMed]
  • Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA. 1991 Jan 2;265(1):86–90. [PubMed]
  • Goodnough LT, Soegiarso RW, Geha AS. Blood lost and blood transfused in coronary artery bypass graft operation as implications for blood transfusion and blood conservation strategies. Surg Gynecol Obstet. 1993 Oct;177(4):345–351. [PubMed]
  • Czer LS, Shoemaker WC. Optimal hematocrit value in critically ill postoperative patients. Surg Gynecol Obstet. 1978 Sep;147(3):363–368. [PubMed]
  • Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med. 1992 Mar 1;116(5):393–402. [PubMed]
  • Goodnough LT, Johnston MF, Ramsey G, Sayers MH, Eisenstadt RS, Anderson KC, Rutman RC, Silberstein LE. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. Ann Thorac Surg. 1990 Oct;50(4):675–683. [PubMed]
  • Contreras M, Ala FA, Greaves M, Jones J, Levin M, Machin SJ, Morgan C, Murphy W, Napier JA, Thomson AR. Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Transfus Med. 1992 Mar;2(1):57–63. [PubMed]
  • Johnson RG, Thurer RL, Kruskall MS, Sirois C, Gervino EV, Critchlow J, Weintraub RM. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg. 1992 Aug;104(2):307–314. [PubMed]
  • Surgenor DM, Wallace EL, Churchill WH, Hao SH, Chapman RH, Collins JJ., Jr Red cell transfusions in coronary artery bypass surgery (DRGs 106 and 107) Transfusion. 1992 Jun;32(5):458–464. [PubMed]
  • Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery. Transfusion. 1994 Apr;34(4):290–296. [PubMed]
  • de Leval MR, François K, Bull C, Brawn W, Spiegelhalter D. Analysis of a cluster of surgical failures. Application to a series of neonatal arterial switch operations. J Thorac Cardiovasc Surg. 1994 Mar;107(3):914–924. [PubMed]
  • Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990 Nov 1;76(9):1680–1697. [PubMed]
  • Harker LA, Malpass TW, Branson HE, Hessel EA, 2nd, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 Nov;56(5):824–834. [PubMed]
  • Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Ouimet H, Pasche B, Nelson MJ, et al. The platelet function defect of cardiopulmonary bypass. Blood. 1993 Jul 1;82(1):107–117. [PubMed]
  • Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994 Jan 20;367(6460):243–249. [PubMed]
  • Ferraris VA, Ferraris SP, Lough FC, Berry WR. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg. 1988 Jan;45(1):71–74. [PubMed]
  • Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol. 1990 Jan;15(1):15–20. [PubMed]
  • Fiore LD, Brophy MT, Lopez A, Janson P, Deykin D. The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol. 1990 Sep;94(3):292–296. [PubMed]
  • O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991 Dec 5;266(34):23261–23267. [PubMed]
  • Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384–7388. [PubMed]
  • O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993 Sep 13;330(2):156–160. [PubMed]
  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693–11697. [PubMed]
  • Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610–6614. [PubMed]
  • Vane J. Towards a better aspirin. Nature. 1994 Jan 20;367(6460):215–216. [PubMed]
  • Ferraris VA, Rodriguez E, Ferraris SP, Huang M, Gupta A, Bennett JA, Andersen TT, Dunn H, Fenton JW, 2nd, Smith JB. Platelet aggregation abnormalities after cardiopulmonary bypass. Blood. 1994 Jan 1;83(1):299–301. [PubMed]
  • Reich DL, Patel GC, Vela-Cantos F, Bodian C, Lansman S. Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg. 1994 Jul;79(1):4–8. [PubMed]
  • Rawitscher RE, Jones JW, McCoy TA, Lindsley DA. A prospective study of aspirin's effect on red blood cell loss in cardiac surgery. J Cardiovasc Surg (Torino) 1991 Jan-Feb;32(1):1–7. [PubMed]
  • Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost. 1993 Aug 2;70(2):259–262. [PubMed]
  • Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 1993 Dec 1;82(11):3350–3357. [PubMed]
  • Slaughter TF, LeBleu TH, Douglas JM, Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology. 1994 Mar;80(3):520–526. [PubMed]
  • Brister SJ, Ofosu FA, Heigenhauser GJ, Gianese F, Buchanan MR. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Thromb Haemost. 1994 Apr;71(4):468–473. [PubMed]
  • DeAnda A, Jr, Coutre SE, Moon MR, Vial CM, Griffin LC, Law VS, Komeda M, Leung LL, Miller DC. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Surg. 1994 Aug;58(2):344–350. [PubMed]
  • Bagge L, Wahlberg T, Holmer E, Tydén H, Nyström SO, Malm T. Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. Blood Coagul Fibrinolysis. 1994 Apr;5(2):265–272. [PubMed]
  • Walenga JM, Bakhos M, Messmore HL, Fareed J, Pifarre R. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg. 1991 Feb;51(2):271–277. [PubMed]
  • Musial J, Niewiarowski S, Rucinski B, Stewart GJ, Cook JJ, Williams JA, Edmunds LH., Jr Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation. 1990 Jul;82(1):261–273. [PubMed]
  • John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg. 1993 May;105(5):816–822. [PubMed]
  • Iverson LI, Duhaylongsod FG, Young JN, Ecker RR, Ennix CL, Jr, Moretti RL, Farrar M, Hayes R, Lee J, May IA. Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients. Cardiovasc Drugs Ther. 1990 Feb;4(1):269–272. [PubMed]
  • Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, Buss DH, Prough DS, Cordell AR. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg. 1990 Mar;99(3):518–527. [PubMed]
  • Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, Triscott M, Brown CW, Mark LJ, Cordell AR. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 1992 Mar;76(3):393–401. [PubMed]
  • Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg. 1994 Sep;58(3):799–805. [PubMed]
  • Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994 May;71(5):633–640. [PubMed]
  • Valeri CR, Khabbaz K, Khuri SF, Marquardt C, Ragno G, Feingold H, Gray AD, Axford T. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg. 1992 Jul;104(1):108–116. [PubMed]
  • Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, Silverman A, Park M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg. 1992 Jul;104(1):94–107. [PubMed]
  • Singh AK, Feng WC, Bert AA, Rotenberg FA. Warm body, cold heart: myocardial revascularization in 2383 consecutive patients. J Cardiovasc Surg (Torino) 1993 Oct;34(5):415–421. [PubMed]
  • Christakis GT, Koch JP, Deemar KA, Fremes SE, Sinclair L, Chen E, Salerno TA, Goldman BS, Lichtenstein SV. A randomized study of the systemic effects of warm heart surgery. Ann Thorac Surg. 1992 Sep;54(3):449–459. [PubMed]
  • Kavanagh BP, Mazer CD, Panos A, Lichtenstein SV. Effect of warm heart surgery on perioperative management of patients undergoing urgent cardiac surgery. J Cardiothorac Vasc Anesth. 1992 Apr;6(2):127–131. [PubMed]
  • Gravlee GP, Arora S, Lavender SW, Mills SA, Hudspeth AS, Cordell AR, James RL, Brockschmidt JK, Stuart JJ. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg. 1994 Jul;58(1):216–221. [PubMed]
  • Fassin W, Himpe D, Alexander JP, Borms S, Theunissen W, Muylaert P, Van Cauwelaert P. Predictive value of coagulation testing in cardiopulmonary bypass surgery. Acta Anaesthesiol Belg. 1991;42(4):191–198. [PubMed]
  • Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, Lappas DG. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1994 Jan;107(1):271–279. [PubMed]
  • Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1993 Aug;7(4):410–415. [PubMed]
  • Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastography versus coagulation screen. Anesth Analg. 1993 Apr;76(4):694–700. [PubMed]
  • Stern MP, DeVos-Doyle K, Viguera MG, Lajos TZ. Evaluation of post-cardiopulmonary bypass Sonoclot signatures in patients taking nonsteroidal anti-inflammatory drugs. J Cardiothorac Anesth. 1989 Dec;3(6):730–733. [PubMed]
  • Ratnatunga CP, Rees GM, Kovacs IB. Preoperative hemostatic activity and excessive bleeding after cardiopulmonary bypass. Ann Thorac Surg. 1991 Aug;52(2):250–257. [PubMed]
  • Culliford AT, Gitel SN, Starr N, Thomas ST, Baumann FG, Wessler S, Spencer FC. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 1981 Jan;193(1):105–111. [PubMed]
  • Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg. 1990 Mar;49(3):440–444. [PubMed]
  • Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994 Dec;108(6):1076–1082. [PubMed]
  • Lemmer JH., Jr Reporting the results of blood conservation studies: the need for uniform and comprehensive methods. Ann Thorac Surg. 1994 Nov;58(5):1305–1306. [PubMed]
  • Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989 Mar;97(3):364–372. [PubMed]
  • Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth. 1993 Jul;40(7):625–631. [PubMed]
  • Liu B, Belboul A, Rådberg G, Tengborn L, Dernevik L, Roberts D, William-Olsson G. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg. 1993;27(3-4):149–155. [PubMed]
  • Sundt TM, 3rd, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg. 1993 Jun;55(6):1418–1424. [PubMed]
  • Cosgrove DM, 3rd, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 1992 Dec;54(6):1031–1038. [PubMed]
  • Havel M, Grabenwöger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 1994 Mar;107(3):807–810. [PubMed]
  • Lemmer JH, Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 1994 Feb;107(2):543–553. [PubMed]
  • Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 1993 Jan;105(1):147–153. [PubMed]
  • Taylor KM. Improved outcome for seriously ill open heart surgery patients: focus on reoperation and endocarditis. J Heart Lung Transplant. 1993 Jan-Feb;12(1 Pt 1):S14–S18. [PubMed]
  • Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH., Jr Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993 Jul;106(1):1–10. [PubMed]
  • Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg. 1994 Jul;108(1):99–108. [PubMed]
  • Ovrum E, Am Holen E, Abdelnoor M, Oystese R, Ringdal ML. Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg. 1993 Jan;105(1):78–83. [PubMed]
  • Arom KV, Emery RW. Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass. Ann Thorac Surg. 1994 May;57(5):1108–1113. [PubMed]
  • Trinh-Duc P, Wintrebert P, Boulfroy D, Albat B, Thévenet A, Roquefeuil B. Comparaison des effets de l'acide epsilon-aminocaproïque et de l'aprotinine sur le saignement per- et post-opératoire en chirurgie cardiaque. Ann Chir. 1992;46(8):677–683. [PubMed]
  • Karski JM, Teasdale SJ, Norman PH, Carroll JA, Weisel RD, Glynn MF. Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth. 1993 Aug;7(4):431–435. [PubMed]
  • Blauhut B, Harringer W, Bettelheim P, Doran JE, Späth P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994 Dec;108(6):1083–1091. [PubMed]
  • DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest. 1989 Jul;96(1):27–30. [PubMed]
  • Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion. 1994 Jan;34(1):66–71. [PubMed]
  • Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989 Oct 26;321(17):1163–1168. [PubMed]
  • Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Yamamoto S, Konishi H, Horii T, Shibata Y. Subcutaneous use of erythropoietin in heart surgery. Ann Thorac Surg. 1992 Sep;54(3):479–484. [PubMed]
  • Watanabe Y, Fuse K, Konishi T, Kobayasi T, Takazawa K, Konishi H, Shibata Y. Autologous blood transfusion with recombinant human erythropoietin in heart operations. Ann Thorac Surg. 1991 May;51(5):767–772. [PubMed]
  • Neustein SM, Bronheim D, Galla J, Litwak R, Rand J, Scott BH, Hartman AR, Poppers PJ, Bert AA, Feng WC, et al. Case 1--1993. The role of erythropoietin in Jehovah's Witnesses requiring cardiac surgery. J Cardiothorac Vasc Anesth. 1993 Feb;7(1):95–102. [PubMed]
  • Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med. 1986 May 29;314(22):1402–1406. [PubMed]
  • Hackmann T, Gascoyne RD, Naiman SC, Growe GH, Burchill LD, Jamieson WR, Sheps SB, Schechter MT, Townsend GE. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med. 1989 Nov 23;321(21):1437–1443. [PubMed]
  • de Prost D, Barbier-Boehm G, Hazebroucq J, Ibrahim H, Bielsky MC, Hvass U, Lacombe C, Français JL, Desmonts JM. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost. 1992 Aug 3;68(2):106–110. [PubMed]
  • Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology. 1992 Jul;77(1):38–46. [PubMed]
  • Brown MR, Swygert TH, Whitten CW, Hebeler R. Desmopressin acetate following cardiopulmonary bypass: evaluation of coagulation parameters. J Cardiothorac Anesth. 1989 Dec;3(6):726–729. [PubMed]
  • Temeck BK, Bachenheimer LC, Katz NM, Coughlin SS, Wallace RB. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J. 1994 Jun;87(6):611–615. [PubMed]
  • Ansell J, Klassen V, Lew R, Ball S, Weinstein M, VanderSalm T, Okike N, Gratz I, Leslie J, Roberts A, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg. 1992 Jul;104(1):117–123. [PubMed]
  • Reich DL, Hammerschlag BC, Rand JH, Weiss-Bloom L, Perucho H, Galla J, Thys DM. Desmopressin acetate is a mild vasodilator that does not reduce blood loss in uncomplicated cardiac surgical procedures. J Cardiothorac Vasc Anesth. 1991 Apr;5(2):142–145. [PubMed]
  • Downing SW, Edmunds LH., Jr Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg. 1992 Dec;54(6):1236–1243. [PubMed]
  • Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993 Feb;55(2):552–559. [PubMed]
  • Boonstra PW, Gu YJ, Akkerman C, Haan J, Huyzen R, van Oeveren W. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994 Jan;107(1):289–292. [PubMed]
  • Borowiec J, Thelin S, Bagge L, Hultman J, Hansson HE. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg. 1992;26(3):177–185. [PubMed]
  • Jones DR, Hill RC, Hollingsed MJ, Stullken E, Graeber GM, Gustafson RA, Murray GF. Use of heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 1993 Sep;56(3):566–568. [PubMed]
  • von Segesser LK, Garcia E, Turina MI. Low-dose heparin versus full-dose heparin with high-dose aprotinin during cardiopulmonary bypass. A preliminary report. Tex Heart Inst J. 1993;20(1):28–32. [PMC free article] [PubMed]
  • Ferraris VA, Berry WR, Klingman RR. Comparison of blood reinfusion techniques used during coronary artery bypass grafting. Ann Thorac Surg. 1993 Sep;56(3):433–440. [PubMed]
  • Giordano GF, Rivers SL, Chung GK, Mammana RB, Marco JD, Raczkowski AR, Sabbagh A, Sanderson RG, Strug BS. Autologous platelet-rich plasma in cardiac surgery: effect on intraoperative and postoperative transfusion requirements. Ann Thorac Surg. 1988 Oct;46(4):416–419. [PubMed]
  • Jones JW, McCoy TA, Rawitscher RE, Lindsley DA. Effects of intraoperative plasmapheresis on blood loss in cardiac surgery. Ann Thorac Surg. 1990 Apr;49(4):585–590. [PubMed]
  • Tobe CE, Vocelka C, Sepulvada R, Gillis B, Nessly M, Verrier ED, Hofer BO. Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study. J Thorac Cardiovasc Surg. 1993 Jun;105(6):1007–1014. [PubMed]
  • Boey SK, Ong BC, Dhara SS. Preoperative plateletpheresis does not reduce blood loss during cardiac surgery. Can J Anaesth. 1993 Sep;40(9):844–850. [PubMed]
  • Wong CA, Franklin ML, Wade LD. Coagulation tests, blood loss, and transfusion requirements in platelet-rich plasmapheresed versus nonpheresed cardiac surgery patients. Anesth Analg. 1994 Jan;78(1):29–36. [PubMed]
  • Ereth MH, Oliver WC, Jr, Beynen FM, Mullany CJ, Orszulak TA, Santrach PJ, Ilstrup DM, Weaver AL, Williamson KR. Autologous platelet-rich plasma does not reduce transfusion of homologous blood products in patients undergoing repeat valvular surgery. Anesthesiology. 1993 Sep;79(3):540–27A. [PubMed]
  • Mayer ED, Welsch M, Tanzeem A, Saggau W, Späth J, Hummels R, Schmitz W. Reduction of postoperative donor blood requirement by use of the cell separator. Scand J Thorac Cardiovasc Surg. 1985;19(2):165–171. [PubMed]
  • Hall RI, Schweiger IM, Finlayson DC. The benefit of the Hemonetics cell saver apparatus during cardiac surgery. Can J Anaesth. 1990 Sep;37(6):618–623. [PubMed]
  • Parrot D, Lançon JP, Merle JP, Rerolle A, Bernard A, Obadia JF, Caillard B. Blood salvage in cardiac surgery. J Cardiothorac Vasc Anesth. 1991 Oct;5(5):454–456. [PubMed]
  • Boldt J, Zickmann B, Czeke A, Herold C, Dapper F, Hempelmann G. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology. 1991 Sep;75(3):426–432. [PubMed]
  • Boldt J, Kling D, von Bormann B, Züge M, Scheld H, Hempelmann G. Blood conservation in cardiac operations. Cell separation versus hemofiltration. J Thorac Cardiovasc Surg. 1989 Jun;97(6):832–840. [PubMed]
  • Nakamura Y, Masuda M, Toshima Y, Asou T, Oe M, Kinoshita K, Kawachi Y, Tanaka J, Tokunaga K. Comparative study of cell saver and ultrafiltration nontransfusion in cardiac surgery. Ann Thorac Surg. 1990 Jun;49(6):973–978. [PubMed]
  • Sutton RG, Kratz JM, Spinale FG, Crawford FA., Jr Comparison of three blood-processing techniques during and after cardiopulmonary bypass. Ann Thorac Surg. 1993 Oct;56(4):938–943. [PubMed]
  • Lönn U, Peterzén B, Granfeldt H, Casimir-Ahn H. Coronary artery operation with support of the Hemopump cardiac assist system. Ann Thorac Surg. 1994 Aug;58(2):519–523. [PubMed]
  • Sellevold OF, Berg TM, Rein KA, Levang OW, Iversen OJ, Bergh K. Heparin-coated circuit during cardiopulmonary bypass. A clinical study using closed circuit, centrifugal pump and reduced heparinization. Acta Anaesthesiol Scand. 1994 May;38(4):372–379. [PubMed]
  • Cosgrove DM, Amiot DM, Meserko JJ. An improved technique for autotransfusion of shed mediastinal blood. Ann Thorac Surg. 1985 Nov;40(5):519–520. [PubMed]
  • Eng J, Kay PH, Murday AJ, Shreiti I, Harrison DP, Norfolk DR, Barnes I, Hawkey PM, Inglis TJ. Postoperative autologous transfusion in cardiac surgery. A prospective, randomised study. Eur J Cardiothorac Surg. 1990;4(11):595–600. [PubMed]
  • Morris JJ, Tan YS. Autotransfusion: is there a benefit in a current practice of aggressive blood conservation? Ann Thorac Surg. 1994 Aug;58(2):502–508. [PubMed]
  • Page R, Russell GN, Fox MA, Fabri BM, Lewis I, Williets T. Hard-shell cardiotomy reservoir for reinfusion of shed mediastinal blood. Ann Thorac Surg. 1989 Oct;48(4):514–517. [PubMed]
  • Roberts SR, Early GL, Brown B, Hannah H, 3rd, McDonald HL. Autotransfusion of unwashed mediastinal shed blood fails to decrease banked blood requirements in patients undergoing aortocoronary bypass surgery. Am J Surg. 1991 Nov;162(5):477–480. [PubMed]
  • Shirvani R. An evaluation of clinical aspects of post-operative autotransfusion, either alone or in conjunction with pre-operative aspirin, in cardiac surgery. Br J Clin Pract. 1991 Summer;45(2):105–108. [PubMed]
  • Schönberger JP, van Oeveren W, Bredée JJ, Everts PA, de Haan J, Wildevuur CR. Systemic blood activation during and after autotransfusion. Ann Thorac Surg. 1994 May;57(5):1256–1262. [PubMed]
  • Ward HB, Smith RR, Landis KP, Nemzek TG, Dalmasso AP, Swaim WR. Prospective, randomized trial of autotransfusion after routine cardiac operations. Ann Thorac Surg. 1993 Jul;56(1):137–141. [PubMed]
  • Axford TC, Dearani JA, Ragno G, MacGregor H, Patel MA, Valeri CR, Khuri SF. Safety and therapeutic effectiveness of reinfused shed blood after open heart surgery. Ann Thorac Surg. 1994 Mar;57(3):615–622. [PubMed]
  • de Haan J, Schönberger J, Haan J, van Oeveren W, Eijgelaar A. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1993 Dec;106(6):1017–1023. [PubMed]
  • Bouboulis N, Kardara M, Kesteven PJ, Jayakrishnan AG. Autotransfusion after coronary artery bypass surgery: is there any benefit? J Card Surg. 1994 May;9(3):314–321. [PubMed]
  • Tector AJ, Gabriel RP, Matericka WE, Oparah SS, Flemma RJ, Lepley D., Jr Reduction of blood usage in open heart surgery. Chest. 1976 Oct;70(4):454–457. [PubMed]
  • Ochsner JL, Mills NL, Leonard GL, Lawson N. Fresh autologous blood transfusions with extracorporeal circulation. Ann Surg. 1973 Jun;177(6):811–817. [PubMed]
  • Petry AF, Jost J, Sievers H. Reduction of homologous blood requirements by blood-pooling at the onset of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994 May;107(5):1210–1214. [PubMed]
  • Britton LW, Eastlund DT, Dziuban SW, Foster ED, McIlduff JB, Canavan TE, Older TM. Predonated autologous blood use in elective cardiac surgery. Ann Thorac Surg. 1989 Apr;47(4):529–532. [PubMed]
  • Owings DV, Kruskall MS, Thurer RL, Donovan LM. Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use. JAMA. 1989 Oct 13;262(14):1963–1968. [PubMed]
  • Love TR, Hendren WG, O'Keefe DD, Daggett WM. Transfusion of predonated autologous blood in elective cardiac surgery. Ann Thorac Surg. 1987 May;43(5):508–512. [PubMed]
  • Schmoeckel M, Nollert G, Mempel M, Mempel W, Reichart B. Effects of recombinant human erythropoietin on autologous blood donation before open heart surgery. Thorac Cardiovasc Surg. 1993 Dec;41(6):364–368. [PubMed]
  • Toy PT, Strauss RG, Stehling LC, Sears R, Price TH, Rossi EC, Collins ML, Crowley JP, Eisenstaedt RS, Goodnough LT, et al. Predeposited autologous blood for elective surgery. A national multicenter study. N Engl J Med. 1987 Feb 26;316(9):517–520. [PubMed]
  • Gravlee GP. Con: autologous blood collection is not useful for elective coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 1994 Apr;8(2):238–241. [PubMed]
  • Zipparo L, Gibson J. Study of the actual and potential utilization of autologous blood donation in four Central Sydney Area hospitals. J Qual Clin Pract. 1994 Jun;14(2):65–75. [PubMed]
  • Van Dyck MJ, Baele PL, Leclercq P, Bertrand M, Brohet C. Autologous blood donation before myocardial revascularization: a Holter-electrocardiographic analysis. J Cardiothorac Vasc Anesth. 1994 Apr;8(2):162–167. [PubMed]
  • Ferguson KJ, Strauss RG, Toy PT. Physician recommendation as the key factor in patients' decisions to participate in preoperative autologous blood donation programs: Preoperative Autologous Blood Donation Study Group. Am J Surg. 1994 Jul;168(1):2–5. [PubMed]
  • Cordell AR, Lavender SW. An appraisal of blood salvage techniques in vascular and cardiac operations. Ann Thorac Surg. 1981 May;31(5):421–425. [PubMed]
  • Keeling MM, Gray LA, Jr, Brink MA, Hillerich VK, Bland KI. Intraoperative autotransfusion. Experience in 725 consecutive cases. Ann Surg. 1983 May;197(5):536–541. [PubMed]
  • Giordano GF, Goldman DS, Mammana RB, Marco JD, Nestor JD, Raczkowski AR, Rivers SL, Sanderson RG, Strug BS, Sandler SG. Intraoperative autotransfusion in cardiac operations. Effect on intraoperative and postoperative transfusion requirements. J Thorac Cardiovasc Surg. 1988 Sep;96(3):382–386. [PubMed]
  • Millar AB, Armstrong L, van der Linden J, Moat N, Ekroth R, Westwick J, Scallan M, Lincoln C. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg. 1993 Dec;56(6):1499–1502. [PubMed]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute